Catalysts Abound For Nuvilex, Inc.
January 22 2014 - 9:30AM
Access Wire
Baltimore, Maryland - Goldman Small Cap Research, a stock market
research firm focused on the small cap and micro cap sectors,
recently published a new research update on Nuvilex Inc. (OTCQB –
NVLX). In the update, senior analyst Rob Goldman outlines his
latest thesis.
"A series of recent landmark events in the marijuana and
medical marijuana space, along with a revaluation of biotechs, are
set to serve as triggers prompting the accumulation and rise of
Nuvilex’s stock back to the levels enjoyed roughly 9 months
ago."
Nuvilex is a biotechnology company with the rights to a novel
cellulose-based live-cell encapsulation technology, called
Cell-in-a-BoxTM, that will be used as a platform upon which
treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being built.
Nuvilex's treatment for pancreatic cancer involves the use of the
widely used anticancer prodrug, ifosfamide, together with
encapsulated live cells that convert ifosfamide into its active or
"cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana
Sciences, Inc., is dedicated to the development of cancer
treatments based upon the well-known chemical constituents of
marijuana. Nuvilex is exploring ways in which the
Cell-in-a-BoxTM technology may play a role in these
efforts.
According to Goldman, the aforementioned triggers include a
surge of interest in, and validation of, medical marijuana and the
publicly traded firms that operate in the space. Catalysts cited in
the research update include a tacit marijuana endorsement by
President Obama, which could give a huge shot in the arm to the
sector. Plus, given that Colorado’s tax revenue-generating pot
shops cannot keep product on the shelves, cash-strapped states and
municipalities may view a softening stance on this topic as a
tangible opportunity to generate real revenue.
In addition, the swift and broad shift in support toward medical
marijuana will likely be enhanced during the 2- week Super Bowl
marketing period. Since the two participants hail from the states
that have legalized marijuana, it is likely that proponents will
flood the media with stories on the topic, placing it near the top
of the talking points food chain.
Finally, Goldman notes that major moves have occurred of late in
other anti-cancer stocks while biotech investors seek to find the
next biotech slated to move in concert with the launch of upcoming
events. With a series of milestone events ahead for the
Company, investors could enjoy similar moves as these milestones
are achieved, as evidenced by the achievements of its peer group
and the subsequent rises in their stock prices.
About Goldman Small Cap Research: Led by former
Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman
Small Cap Research produces sponsored and non-sponsored small cap
and micro cap stock research reports, articles, daily stock market
blogs, and popular investment newsletters. Goldman Small Cap
Research is not in any way affiliated with Goldman Sachs &
Co.
A sponsored Goldman Small Cap Research report, update,
newsletter, or article is not intended as an offering,
recommendation, or a solicitation of an offer to buy or sell the
securities mentioned or discussed. Please read all associated
full disclosures, disclaimers, and analyst background on our
website before investing. Neither Goldman Small Cap Research nor
its parent is a registered investment adviser or broker-dealer with
FINRA or any other agency. To download our research, view our
disclosures, or for more information, visit
www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB – NVLX): Nuvilex,
Inc. is an international biotechnology firm focused on developing
and preparing to commercialize treatments for cancer, diabetes and
other diseases based on the live, therapeutically valuable,
encapsulated cells platform. The Company is leveraging its cancer
biology and clinical oncology research experience and expertise,
particularly for use in oncology treatments, in addition to
initiating oncology applications of medical marijuana. For
more information visit: www.nuvilex.com.
Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com